Miracell Stem Cell ‘Smart Mcell 2’ Participates in Germany’s Medica
Stem cell specialist Miracell announced on the 29th that it participated in Germany’s “MEDICA 2021,” the world’s largest medical device exhibition.
“MEDICA 2021” was held from November 15th to 18th at the Düsseldorf International Exhibition Center in Germany.
Over 3,500 companies from 150 countries participated and 46,000 visitors attended.
Miracell showcased its “state-of-the-art bio-stem cell extraction system,” developed using domestic technology.
The SMART M-CELL2 is a “bone marrow and blood stem cell extraction device with a cell separation vessel capable of selective separation.”
It is a cutting-edge bio-regenerative medical device that concentrates bone marrow and blood through cell separation and automatic separation to extract large quantities of isolated stem cells.
Miracell CEO Shin Hyun-soon explained, “At this exhibition, Miracell’s stem cell treatment videos and pre- and post-treatment data garnered attention from international buyers. Questions poured in about stem cell extraction and treatment using SmartMcell2, as well as its effectiveness, and we secured contracts from European buyers.”
He continued, “European countries like Germany, the UK, and France were particularly interested in post-COVID-19 medical devices and ‘immuno-healthcare,’ and this was a great opportunity to widely promote the benefits of stem cells through Miracell’s unique technology.”
“We demonstrated to buyers the results of our treatment of skin diseases, including rare and intractable psoriasis, and introduced Miracell’s bio-stem cell system, which has received all five European CE certifications.”
Miracell’s SmartMcell2 is currently undergoing global patent applications in over 40 countries, including the US Food and Drug Administration (FDA).
The company is currently preparing for the 2022 Arab Health Fair in Dubai.
Meanwhile, Miracell, through its membership in the Cellpia Global Platform (CGP), has built an organic network with doctors and medical staff at hospitals and clinics both domestically and internationally, sharing its specialized stem cell medical technology. CGP provides education, technology transfer, medical system setup, and marketing services to ensure safe stem cell regenerative medicine treatments for hospitals both domestically and internationally.
By Jeong Myeong-jin (pompom@fnnews.com)